Stoke Therapeutics Outlines Q3 2027 EMPEROR Trial Progress and Plans NDA Submission for Late 2027
Stoke Therapeutics (STOK) provided an update on its EMPEROR clinical program, noting significant progress in patient enrollment and follow-up. CEO Ian Smith reported that approximately 110 of the 162 enrolled patients have successfully completed their week 28 visits, indicating steady execution of the trial protocol. The company is currently focused on FDA alignment and preparations for a commercial launch. Based on current progress, Stoke plans to submit a New Drug Application (NDA) in the second half of 2027. This timeline marks a critical milestone in the company's transition from clinical development toward potential market entry.
Tickers: $STOK
Topics: clinical trial progress FDA alignment quarterly earnings insights